Lexatumumab
Jump to navigation
Jump to search
Template:Short description Template:Drugbox
Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer.[1][2]
HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology.[3]
Development was discontinued in 2015.[4]
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".